Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 28 April 2026 ASX RELEASE QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – March 2026 Key Highlights from the Quarter • Promising data was reported from analysis of mature clinical data from the ACCENT trial, investigating narmafotinib in combination with chemotherapy o Five Complete Responses were identified from independent review of imaging data, along with an Objective Response Rate of 36% o Median Overall Survival was determined at 11.1 months • A large scale production of approx. 13 kg of narmafotinib was completed to GMP standards at Amplia’s contracted production facility • Preclinical data demonstrating the potential of combining narmafotinib with a new class of drugs called kRAS inhibitors was presented at a specialist conference • Mr Hamish George has succeeded Mr Tim Luscombe as the Company’s CFO Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), developing new drugs for the treatment for cancer and fibrosis, reports progress in the ongoing development of narmafotinib along with the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 31 March 2026. Operations Update The Company continues to make significant progress in the development of its best-in-class FAK inhibitor, narmafotinib, for the treatment of metastatic pancreatic cancer. Clinical Trial Updates Over the last quarter the most significant update was provided to the market in March this year. The Company reported mature results from the ACCENT clinical trial which combines narmafotinib with the chemotherapies gemcitabine and Abraxane® . The mature data analysis was derived from a blinded independent review of clinical response data (specifically Computed Tomography (CT) scans) available up to mid-March 2026 by a specialist, globally recognised, contract laboratory. This analysis demonstrated that the combination of narmafotinib with chemotherapy shows a median overall survival of 11.1 months, more than two months improved over chemotherapy alone in the benchmark MPACT study. In addition, an unprecedented five confirmed complete responses (CRs) were recorded, giving a CR rate of 7.8% (5/64). The updated Objective Response Rate (ORR) is 35.9% (23/64), with four patients still enrolled as of March 2026. Notably, narmafotinib is well tolerated by patients and does not contribute significant additional toxicity beyond that already associated with the chemotherapy regimen. Amplia was selected to present these data at the prestigious American Association of Cancer Research annual meeting in April 2026 as an oral presentation in the Advances in Precision Oncology symposium. The Company also presented data from the ACCENT trial in January at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) meeting in San Francisco. This is a specialist conference where oncologists and drug developers in the GI cancer space discuss latest data and trends in the treatment of pancreatic and other cancers. Conference participation and presentations at these and other international meetings is an important phase of our engagement and interaction with collaborators, key opinion leaders and potential commercial partners. This is particularly relevant at this time given the significant developments in the treatment of pancreatic cancer, most notably with the exciting clinical progress of targeted (personalised) therapies. By detailing the promising safety, tolerability and efficacy data for narmafotinib observed in the ACCENT trial, we demonstrate the drug’s significant clinical opportunity in pancreatic cancer when combined with chemotherapy or targeted therapies. The Company’s second clinical trial, AMPLICITY, is exploring the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX. In February, it was announced that two US sites, University of California, Irvine and The Cleveland Clinic, had completed pre-trial activities and would soon begin recruitment for the AMPLICITY trial. These sites joined two existing Australian sites, Epworth Hospital (Melbourne) and Genesis Care (Sydney). In April the Company announced that recruitment to the trial would be discontinued after three cases of dose-limiting toxicity had been observed, in each case related to the chemotherapy and not related to narmafotinib. Five patients remain on study at the two Australian sites and further updates from this study will be reported in due course. Regulatory and Chemistry Manufacturing and Control (CMC) Updates In January the Company announced completion of large-scale production of narmafotinib meeting required purity and quality standards – a major milestone toward Phase 3 readiness. The Company successfully transitioned manufacturing from R&D to a commercial environment in partnership with its Contract Development and Manufacturing Organization (CDMO), achieving greater efficiency and cost savings. Approximately 13 kg of GMP-produced active pharmaceutical ingredient will be subsequently formulated into oral capsules for current and future clinical trials. Manufacturing complies with internationally recognised Good Manufacturing Practice (GMP) standards, ensuring product safety and quality. The Company continues to refine the clinical plan for the registrational study for narmafotinib in pancreatic cancer. Our regulatory team are working closely with our advisers with the aim of a formal meeting engagement with the US FDA mid-year. Preclinical Updates In March, the Company announced that new data on narmafotinib was presented at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics in Los Angeles on March 6. The preclinical findings show narmafotinib boosts the effectiveness of kRAS inhibitors in cancer models by blocking resistance pathways. kRAS inhibitors, currently in development for cancers such as lung, colon, and pancreatic, are being studied worldwide, but side-effects and resistance remain challenges despite encouraging mid-stage clinical data. Operational Updates In February the Company announced the appointment of Mr Hamish George as Chief Financial Officer effective 25 February 2026. Mr George succeeds Mr Tim Luscombe of Bio101 Financial Advisory. Mr George is a Chartered Accountant with degrees from the University of Melbourne and RMIT, previously acted as Amplia’s CFO, and has extensive CFO experience with a range of life sciences and ASX-listed companies. Future Outlook The ACCENT and AMPLICITY trials are ongoing and further updates will be reported as significant findings become available. Planning for new clinical studies with narmafotinib is well underway, including the registration-enabling study of narmafotinib in combination with gemcitabine and Abraxane® .Business Development activities are also progressing in light of the promising data from the ACCENT study. Financial update Amplia finished the March 2026 quarter with a cash position of $27.9 million (December 2025: $31.5 million). During the quarter, the Company had net operating cash outflows of $3.5 million in relation to operating activities (December 2025: $2.4 million inflows). Operating cashflows included: • Outflows of $0.9 million for staff and administration/corporate costs; and • Outflows of $2.8 million for research and development costs, which primarily related to trial costs, Contract Research Organisation (CRO), manufacturing and other CMC related costs incurred in relation to the ACCENT and AMPLICITY clinical trials. Payments to Related Entities In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors’ fees, salaries and superannuation. Total payments made for the quarter equals $147,500 and relate to payments to the CEO/Managing Director in line with employment contracts and payments to the Non-Executive Directors. - End - For Further Information Dr. Christopher Burns CEO and Managing Director Chris@ampliatx.com www.ampliatx.com This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over- expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first- line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a response rate of 31%, superior to chemotherapy alone and an interim PFS of 7.7 months has been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at two sites in Australia, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients. Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 1 + See chapter 19 of the ASX Listing Rules for defined terms. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity AMPLIA THERAPEUTICS LIMITED ABN Quarter ended (“current quarter”) 16 165 160 841 31 March 2026 Consolidated statement of cash flows Current quarter $A’000 Year to date (12 months) $A’000 1. Cash flows from operating activities - - 1.1 Receipts from customers 1.2 Payments for (2,817) (9,313) (a) research and development (b) product manufacturing and operating costs - - (c) advertising and marketing - - (d) leased assets - - (e) staff costs (377) (1,670) (f) administration and corporate costs (536) (2,180) 1.3 Dividends received (see note 3) - - 1.4 Interest received 240 664 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid - 1.7 Government grants and tax incentives - 3,784 1.8 Other (payment of GST) (45) (21) 1.9 Net cash from / (used in) operating activities (3,535) (8,736) 2. Cash flows from investing activities - - 2.1 Payments to acquire or for: (a) entities (b) businesses - - (c) property, plant and equipment (6) (34) (d) investments - - (e) intellectual property - - (f) other non-current assets - - Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 2 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $A’000 Year to date (12 months) $A’000 2.2 Proceeds from disposal of: - - (a) entities (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received (see note 3) - - 2.5 Other (bank guarantee and security deposit) - (64) 2.6 Net cash from / (used in) investing activities (6) (98) 3. Cash flows from financing activities - 27,647 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - 238 3.4 Transaction costs related to issues of equity securities or convertible debt securities - (1,858) 3.5 Proceeds from borrowings - - 3.6 Repayment of borrowings - - 3.7 Transaction costs related to loans and borrowings - - 3.8 Dividends paid - - 3.9 Other (repayment of lease liability) (27) (86) 3.10 Net cash from / (used in) financing activities (27) 25,941 4. Net increase / (decrease) in cash and cash equivalents for the period 31,497 10,863 4.1 Cash and cash equivalents at beginning of period 4.2 Net cash from / (used in) operating activities (item 1.9 above) (3,535) (8,736) 4.3 Net cash from / (used in) investing activities (item 2.6 above) (6) (98) Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 3 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $A’000 Year to date (12 months) $A’000 4.4 Net cash from / (used in) financing activities (item 3.10 above) (27) 25,941 4.5 Effect of movement in exchange rates on cash held (75) (116) 4.6 Cash and cash equivalents at end of period 27,854 27,854 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts Current quarter $A’000 Previous quarter $A’000 5.1 Bank balances 1,472 2,261 5.2 Call deposits 26,382 29,236 5.3 Bank overdrafts - - 5.4 Other (provide details) 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 27,854 31,497 6. Payments to related parties of the entity and their associates Current quarter $A'000 6.1 Aggregate amount of payments to related parties and their associates included in item 1 148 6.2 Aggregate amount of payments to related parties and their associates included in item 2 - Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments. The amount at 6.1 includes Director fees and salary (including superannuation) for the CEO and Managing Director and Non-Executive Directors. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 4 + See chapter 19 of the ASX Listing Rules for defined terms. 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $A’000 Amount drawn at quarter end $A’000 7.1 Loan facilities - - 7.2 Credit standby arrangements - - 7.3 Other (please specify) - - 7.4 Total financing facilities - - 7.5 Unused financing facilities available at quarter end - 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. N/A 8. Estimated cash available for future operating activities $A’000 8.1 Net cash from / (used in) operating activities (item 1.9) (3,535) 8.2 Cash and cash equivalents at quarter end (item 4.6) 27,854 8.3 Unused finance facilities available at quarter end (item 7.5) - 8.4 Total available funding (item 8.2 + item 8.3) 27,854 8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 7.9 Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5. 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: N/A 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: N/A 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: N/A Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 5 + See chapter 19 of the ASX Listing Rules for defined terms. Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. 28 April 2026 Date: ................................................................................... The Board of Directors Authorised by: ................................................................................... (Name of body or officer authorising release – see note 4) Notes 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so. 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report. 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity. 4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”. 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.